Report cover image

Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 185 Pages
SKU # IRE18436308

Description

Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Global Forecast 2024-2030


The Biosimilar Monoclonal Antibodies Market size was estimated at USD 7.69 billion in 2023 and expected to reach USD 9.47 billion in 2024, at a CAGR 23.19% to reach USD 33.14 billion by 2030.

Global Biosimilar Monoclonal Antibodies Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biosimilar Monoclonal Antibodies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biosimilar Monoclonal Antibodies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biosimilar Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include 3SBio Inc., AbbVie, Inc., Amgen Inc., Biocon Limited, BioXpress Therapeutics SA, C.H. Boehringer Sohn AG & Co. KG, Celltrion Healthcare Co Ltd., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Ltd, Genor BioPharma Co. Ltd, Hisun Pharmaceutical, Intas Pharmaceuticals Limited, Novartis AG, Pfizer, Inc., Reliance Life Sciences, and Samsung Biologics.

Market Segmentation & Coverage



This research report categorizes the Biosimilar Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
Abciximab
Adalimumab
Bevacizumab
Infliximab
Rituximab
Trastuzumab
Application
Diagnostic
MABs in Biochemical Analysis
Cancers
Hormonal Disorders
Infectious Diseases
Pregnancy
MABs in Diagnostic Imaging
Atherosclerosis
Bacterial Infections
Cancers
Cardiovascular Diseases
Deep Vein Thrombosis
Protein Purification
Therapeutic
MABs as Direct Therapeutic Agents
MABs as Targeting Agents in Therapy
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Biosimilar Monoclonal Antibodies Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biosimilar Monoclonal Antibodies Market?
3. What are the technology trends and regulatory frameworks in the Biosimilar Monoclonal Antibodies Market?
4. What is the market share of the leading vendors in the Biosimilar Monoclonal Antibodies Market?
5. Which modes and strategic moves are suitable for entering the Biosimilar Monoclonal Antibodies Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

185 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Biosimilar Monoclonal Antibodies Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
5.1.1.2. Growth in geriatric population and rising incidence of cancer and other chronic diseases
5.1.1.3. Increasing healthcare expenditure in economies
5.1.2. Restraints
5.1.2.1. Government regulations towards the absence of pre-analytical tests
5.1.3. Opportunities
5.1.3.1. Rising number of inorganic strategies for the expansion of production facility
5.1.3.2. Focus on R&D to introduce innovative product pipeline
5.1.4. Challenges
5.1.4.1. Complexities associated with manufacturing processes
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Biosimilar Monoclonal Antibodies Market, by Drug Class
6.1. Introduction
6.2. Abciximab
6.3. Adalimumab
6.4. Bevacizumab
6.5. Infliximab
6.6. Rituximab
6.7. Trastuzumab
7. Biosimilar Monoclonal Antibodies Market, by Application
7.1. Introduction
7.2. Diagnostic
7.3.1. MABs in Biochemical Analysis
7.3.2.1. Cancers
7.3.2.2. Hormonal Disorders
7.3.2.3. Infectious Diseases
7.3.2.4. Pregnancy
7.3.2. MABs in Diagnostic Imaging
7.3.3.1. Atherosclerosis
7.3.3.2. Bacterial Infections
7.3.3.3. Cancers
7.3.3.4. Cardiovascular Diseases
7.3.3.5. Deep Vein Thrombosis
7.3. Protein Purification
7.4. Therapeutic
7.5.1. MABs as Direct Therapeutic Agents
7.5.2. MABs as Targeting Agents in Therapy
8. Americas Biosimilar Monoclonal Antibodies Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Biosimilar Monoclonal Antibodies Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Biosimilar Monoclonal Antibodies Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. 3SBio Inc.
12.1.2. AbbVie, Inc.
12.1.3. Amgen Inc.
12.1.4. Biocon Limited
12.1.5. BioXpress Therapeutics SA
12.1.6. C.H. Boehringer Sohn AG & Co. KG
12.1.7. Celltrion Healthcare Co Ltd.
12.1.8. Coherus BioSciences, Inc.
12.1.9. Dr. Reddy’s Laboratories Ltd
12.1.10. Genor BioPharma Co. Ltd
12.1.11. Hisun Pharmaceutical
12.1.12. Intas Pharmaceuticals Limited
12.1.13. Novartis AG
12.1.14. Pfizer, Inc.
12.1.15. Reliance Life Sciences
12.1.16. Samsung Biologics
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 2. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2023 VS 2030
FIGURE 3. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET DYNAMICS
FIGURE 7. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us